Form 8-K - Current report:
SEC Accession No. 0001683168-25-001940
Filing Date
2025-03-27
Accepted
2025-03-27 17:15:08
Documents
14
Period of Report
2025-03-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K coeptis_8k.htm   iXBRL 8-K 30354
  Complete submission text file 0001683168-25-001940.txt   247367

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE coep-20250321.xsd EX-101.SCH 3262
3 XBRL DEFINITION FILE coep-20250321_def.xml EX-101.DEF 26556
4 XBRL LABEL FILE coep-20250321_lab.xml EX-101.LAB 36480
5 XBRL PRESENTATION FILE coep-20250321_pre.xml EX-101.PRE 25180
16 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5581
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 25780514
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)